Cancer Res Treat.  2017 Jul;49(3):595-606. 10.4143/crt.2016.034.

Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer

Affiliations
  • 1Department of Obstetrics and Gynecology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 2Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. garden.lee7@gmail.com, bgkim@skku.edu

Abstract

PURPOSE
This study was conducted to investigate whether a proton pump inhibitor (PPI) could enhance chemosensitivity via the inhibition of vacuolar-type H⁺ ATPase (V-ATPase) in cervical cancer.
MATERIALS AND METHODS
The expression of V-ATPase was evaluated in 351 formalin-fixed, paraffin-embedded human cervical cancer tissues using immunohistochemistry and compared with clinicopathologic risk factors for disease prognosis. The influence of cell proliferation and apoptosis following V-ATPase siRNA transfection or esomeprazole pretreatment was assessed in cervical cancer cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and enzyme-linked immunosorbent assay, respectively.
RESULTS
Immunohistochemical analysis revealed that V-ATPase was expressed in about 60% of cervical cancer tissue samples (211/351), and the expression was predominantly found in adenocarcinoma histology (p=0.016). Among patients with initially bulky cervical cancer (n=89), those with V-ATPase expression had shorter disease-free survival (p=0.005) and overall survival (p=0.023). Co-treatment with V-ATPase siRNA or esomeprazole with paclitaxel significantly decreased the cell proliferation of cervical cancer cell lines, including HeLa and INT407, compared to cell lines treated with paclitaxel alone (p < 0.01). Moreover, V-ATPase siRNA or esomeprazole followed by paclitaxel significantly increased the expression of active caspase-3 in these cells compared to cells treated with paclitaxel alone (both, p < 0.05).
CONCLUSION
V-ATPase was predominantly expressed in cervical adenocarcinoma, and the expression of V-ATPases was associated with poor prognosis. The inhibition of V-ATPase via siRNA or PPI (esomeprazole) might enhance the chemosensitivity of paclitaxel in cervical cancer cells.

Keyword

Uterine cervical neoplasms; Vacuolar proton-translocating ATPases; Proton pump inhibitors; Esomeprazole; Small interfering RNA; Antineoplastic agents

MeSH Terms

Adenocarcinoma
Adenosine Triphosphatases
Antineoplastic Agents
Apoptosis
Caspase 3
Cell Line
Cell Proliferation
Disease-Free Survival
Enzyme-Linked Immunosorbent Assay
Esomeprazole
Humans
Immunohistochemistry
Paclitaxel*
Prognosis
Proton Pump Inhibitors
Proton Pumps*
Protons*
Risk Factors
RNA, Small Interfering
Transfection
Uterine Cervical Neoplasms*
Vacuolar Proton-Translocating ATPases
Adenosine Triphosphatases
Antineoplastic Agents
Caspase 3
Esomeprazole
Paclitaxel
Proton Pump Inhibitors
Proton Pumps
Protons
RNA, Small Interfering
Vacuolar Proton-Translocating ATPases

Figure

  • Fig. 1. Vacuolar-type H+ ATPase (V-ATPase) was predominantly expressed in cervical adenocarcinoma, which was associated with poor prognosis. (A) Representative V-ATPase staining from cervical cancer (a, no staining; b, weak staining; c, moderate staining; d, strong staining, ×400). (B) Expression of V-ATPase in cervical cancer according to histology based on immunohistochemistry (IHC) (n=351). (C) Kaplan-Meier curves showed disease-free survival and overall survival according to V-ATPase expression in 89 patients with bulky cervical cancers (tumor diameter > 4 cm). (D) Kaplan-Meier curves showed disease-free survival according to cell type in 55 patients with bulky V-ATPase positive tumors.

  • Fig. 2. (A) Expression of vacuolar-type H+ ATPase (V-ATPase) in various cervical cancer cell lines. (B) Expression of V-ATPase was decreased by V-ATPase siRNA in HeLa and INT407 cells. (C) The effects of V-ATPase siRNA transfection on cell viability with paclitaxel in HeLa and INT407 cells. GAPDH, glyceraldehyde 3-phosphate dehydrogenase. *p < 0.05, **p < 0.01.

  • Fig. 3. Effects of vacuolar-type H+ ATPase (V-ATPase) siRNA transfection on cell apoptosis with paclitaxel in HeLa and INT407 cells. (A) Cell death was observed by light microscopy in HeLa and INT407 cells (×100). (B) Expression of active caspase-3 was measured by enzyme-linked immunosorbent assay in HeLa and INT407 cells. *p < 0.05.

  • Fig. 4. Effects of esomeprazole (ESOM) pretreatment on cell survival and apoptosis with paclitaxel in HeLa and INT407 cells. (A) ESOM pretreatment significantly enhanced the cytotoxicity of paclitaxel in HeLa (37%, p < 0.01) and INT407 (47%, p < 0.01) cells when compared with paclitaxel treatment alone. (B) Cell death was observed by light microscopy in HeLa and INT407 cells (×100). (C) Expression of active caspase-3 was measured by enzyme-linked immunosorbent assay in HeLa and INT407 cells. *p < 0.05, **p < 0.01.

  • Fig. 5. Changes in intracellular pH. (A) Live-cell imaging of the BCECF intensity in HeLa cells with/without esomeprazole (ESOM) treatment using a LSM700 confocal microscope (×400). (B) The cytosolic pH of HeLa and INT407 cells treated with 30 μg/mL ESOM for 3 hours decreased (both, p < 0.01). *p < 0.05.


Reference

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893–917.
Article
2. Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol. 2010; 116:140–6.
Article
3. Lee YY, Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH, et al. A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. Gynecol Oncol. 2011; 120:439–43.
Article
4. Peiretti M, Zapardiel I, Zanagnolo V, Landoni F, Morrow CP, Maggioni A. Management of recurrent cervical cancer: a review of the literature. Surg Oncol. 2012; 21:e59.
Article
5. Nishi T, Forgac M. The vacuolar (H+)-ATPases: nature's most versatile proton pumps. Nat Rev Mol Cell Biol. 2002; 3:94–103.
6. Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ. Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol. 1993; 265(4 Pt 1):C1015–29.
Article
7. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993; 53:21–5.
8. Sabolic I, Brown D, Verbavatz JM, Kleinman J. H(+)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole. Am J Physiol. 1994; 266(6 Pt 2):F868–77.
Article
9. Ha SY, Lee J, Jang J, Hong JY, Do IG, Park SH, et al. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. Int J Cancer. 2015; 136:1629–35.
Article
10. Huang L, Lu Q, Han Y, Li Z, Zhang Z, Li X. ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells. Diagn Pathol. 2012; 7:180.
Article
11. Lu Q, Lu S, Huang L, Wang T, Wan Y, Zhou CX, et al. The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer. Diagn Pathol. 2013; 8:145.
Article
12. De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res. 2007; 67:5408–17.
Article
13. Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004; 96:1702–13.
Article
14. Boyer MJ, Tannock IF. Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions. Cancer Res. 1992; 52:4441–7.
15. Zhdanov AV, Dmitriev RI, Papkovsky DB. Bafilomycin A1 activates respiration of neuronal cells via uncoupling associated with flickering depolarization of mitochondria. Cell Mol Life Sci. 2011; 68:903–17.
Article
16. Lv C, Yang X, Yu B, Ma Q, Liu B, Liu Y. Blocking the Na+/H+ exchanger 1 with cariporide (HOE642) reduces the hypoxiainduced invasion of human tongue squamous cell carcinoma. Int J Oral Maxillofac Surg. 2012; 41:1206–10.
17. Thomas GM. Improved treatment for cervical cancer: concurrent chemotherapy and radiotherapy. N Engl J Med. 1999; 340:1198–200.
18. Robova H, Rob L, Halaska MJ, Pluta M, Skapa P, Strnad P, et al. High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer. Gynecol Oncol. 2013; 128:49–53.
Article
19. Yee GP, de Souza P, Khachigian LM. Current and potential treatments for cervical cancer. Curr Cancer Drug Targets. 2013; 13:205–20.
20. Reshkin SJ, Greco MR, Cardone RA. Role of pHi, and proton transporters in oncogene-driven neoplastic transformation. Philos Trans R Soc Lond B Biol Sci. 2014; 369:20130100.
21. Boedtkjer E, Bunch L, Pedersen SF. Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: similarities, differences, and implications for cancer therapy. Curr Pharm Des. 2012; 18:1345–71.
Article
22. Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res. 2007; 67:10627–30.
23. Larsson H, Mattson H, Sundell G, Carlsson E. Animal pharmacodynamics of omeprazole: a survey of its pharmacological properties in vivo. Scand J Gastroenterol Suppl. 1985; 108:23–35.
24. Morimura T, Fujita K, Akita M, Nagashima M, Satomi A. The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma. Pediatr Surg Int. 2008; 24:1087–94.
Article
25. Yeo M, Kim DK, Kim YB, Oh TY, Lee JE, Cho SW, et al. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res. 2004; 10:8687–96.
Article
26. Yamagata M, Tannock IF. The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and antitumour effects. Br J Cancer. 1996; 73:1328–34.
Article
27. Udelnow A, Kreyes A, Ellinger S, Landfester K, Walther P, Klapperstueck T, et al. Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS One. 2011; 6:e20143.
Article
28. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007; 99:1441–54.
Article
29. Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res. 2010; 29:44.
Article
30. De Milito A, Luciani F, Fais S. How to overcome cisplatin resistance through proton pump inhibitors. In : Bonetti A, Leone R, Muggia FM, Howell SB, editors. Platinum and other heavy metal compounds in cancer chemotherapy. New York: Springer;2009. p. 109–14.
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr